Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosusThomas Dörner, Yoshiya Tanaka, Ernst R Dow, Alisa E Koch, Maria Silk, Jorge A Ross Terres, Jonathan T Sims, Zhe Sun, Inmaculada de la Torre, Michelle Petri
24 May 2022
Biological impact of iberdomide in patients with active systemic lupus erythematosusPeter E Lipsky, Ronald van Vollenhoven, Thomas Dörner, Victoria P Werth, Joan T Merrill, Richard Furie, Milan Petronijevic, Benito Velasco Zamora, Maria Majdan, Fedra Irazoque-Palazuelos, Robert Terbrueggen, Nikolay Delev, Michael Weiswasser, Shimon Korish, Mark SternSee the full list of authors
27 April 2022
Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart functionSabrina Meisgen, Malin Hedlund, Aurelie Ambrosi, Lasse Folkersen, Vijole Ottosson, David Forsberg, Gudny Ella Thorlacius, Luca Biavati, Linn Strandberg, Johannes Mofors, Daniel Ramskold, Sabrina Ruhrmann, Lauro Meneghel, William Nyberg, Alexander EspinosaSee the full list of authors
25 April 2022
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortMay Yee Choi, Ann Elaine Clarke, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J Wallace, David Isenberg, Anisur Rahman, Joan T Merrill, Paul R FortinSee the full list of authors
25 March 2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology AllianceManuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, Ali Duarte-García, Cristina Reátegui-Sokolova, Ann Elaine Clarke, Leanna Wise, Guillermo J Pons-Estel, Maria Jose Santos, Sasha Bernatsky, Sandra Lúcia Euzébio Ribeiro, Samar Al Emadi, Jeffrey A Sparks, Tiffany Y -T Hsu, Naomi J PatelSee the full list of authors
16 February 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala
25 March 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C. Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius Albulescu, Micki Hultquist, Raj Tummala
17 May 2022
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupusYusuke Takeshima, Yukiko Iwasaki, Masahiro Nakano, Yuta Narushima, Mineto Ota, Yasuo Nagafuchi, Shuji Sumitomo, Tomohisa Okamura, Keith Elkon, Kazuyoshi Ishigaki, Akari Suzuki, Yuta Kochi, Kazuhiko Yamamoto, Keishi Fujio
2 March 2022
Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLEErika L Hubbard, David S Pisetsky, Peter E Lipsky
3 February 2022
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritisDavid Jayne, Brad Rovin, Eduardo F Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Catharina Lindholm
10 February 2022